Background {#Sec1}
==========

Pancreatic cancer is the seventh leading cause of global cancer death \[[@CR1]\] and the third most common cause of cancer-related death in the United States \[[@CR2]\]. It is usually diagnosed at an advanced stage, and 80--90% of patients with pancreatic cancer have unresectable tumors. For patients with metastatic disease, the 5-year survival rate is less than 10% \[[@CR3]\]. The National Comprehensive Cancer Network (NCCN) 2019 guidelines recommend chemotherapy with FOLFIRINOX \[[@CR4]\] or gemcitabine plus nab-paclitaxel \[[@CR5]\] as preferred options for patients with an acceptable baseline performance status (Eastern Cooperative Oncology Group performance status \[ECOG PS\] score of 0--1) \[[@CR6]\]. Cell-autonomous mechanisms of resistance to chemotherapy, however, further limit therapeutic options, and there have been multiple negative randomized trials in the adjuvant and first-line setting \[[@CR7]\]. Immunotherapies explored so far have not demonstrated improved benefits over chemotherapy perhaps because tumor cells are nonimmunogenic in nature and are characterized by poor antigenicity \[[@CR8]\]. Only 1% of patients with pancreatic cancer have tumors with high levels of microsatellite instability (MSI-H) or mismatch repair deficiencies (dMMR) and are considered to be candidates for checkpoint inhibitors \[[@CR9], [@CR10]\]. Furthermore, in the small minority of patients with pancreatic cancer who have germline *BRCA* mutations (4--7%), progression-free survival (PFS) following poly(adenosine diphosphate--ribose) polymerase (PARP) inhibitor therapy was not influenced by prior response to platinum-based therapy \[[@CR11]\].

In general, most guidelines recommend the use of gemcitabine as monotherapy or as part of a combination therapy regimen for patients previously treated with FOLFIRINOX or other fluoropyrimidine-based therapy \[[@CR6]\]. For patients previously treated with gemcitabine-based regimens, 5-FU--based therapy including FOLFIRI, OFF, and FOLFOX has been recommended \[[@CR6]\]. Recently, the Food and Drug Administration (FDA) approved nanoliposomal irinotecan in combination with 5-FU and leucovorin as second-line therapy after previous gemcitabine-based therapy (NAPOLI-1) \[[@CR12]\]. Based on the findings from the NAPOLI-1 study, updated guidelines recommend the use of nanoliposomal irinotecan with fluorouracil and leucovorin in patients with metastatic pancreatic cancer after prior gemcitabine-based therapy \[[@CR13]\]. In the NAPOLI-1 study, the median overall survival (OS) was 6.1 months (95% confidence interval \[CI\] 4.8--8.9) for the combination of nanoliposomal irinotecan/5-FU/leucovorin compared with 4.2 months (95% CI 3.3--5.3) for 5-FU/leucovorin alone with a hazard ratio of 0.67 (95% CI 0.49--0.92; *P* = .012) in patients with Karnofsky PS scores of 70 and above \[[@CR12]\]. Survival benefits of this regimen were numerically similar to historically 5-FU--based therapy. For example, the phase III CONKO-003 trial of OFF demonstrated a median OS of 5.9 months \[[@CR14]\]. More recently, a randomized phase II trial of mFOLFOX reported a median OS of 6.7 months in patients previously treated with gemcitabine \[[@CR15]\], and despite not meeting its primary endpoint, the phase III PANCREOX study of mFOLFOX demonstrated a median OS of 6.1 months \[[@CR16]\].

In the past, many prognostic factors have been identified and considered, such as hemoglobin level, tumor burden, liver metastases, venous thromboembolism, baseline expression of B7H1 or B7H4, and baseline CA19--9 \[[@CR17]--[@CR23]\]. One of the most significant prognostic factors is baseline ECOG PS. For example, one small, single-arm, phase II cohort study demonstrated a median OS for second-line FOLFOX with a median survival of 4.3 months. When patients were stratified by baseline ECOG PS, the median OS was 5.9 months for patients with adequate PS (i.e., ECOG PS scores, 0--1) and 2.6 months for those with ECOG PS scores ≥2 \[[@CR24]\]. In this paper, we performed a systematic review to better characterize the safety and efficacy of FOLFOX treatment for patients with metastatic pancreatic cancer following prior gemcitabine-based therapy. A Bayesian meta-analysis with adjustment of patient PS was conducted to evaluate the median OS and cross-compare with nanoliposomal irinotecan combination therapy.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

Studies were identified from searches conducted in [PubMed.gov](http://pubmed.gov), [FDA.gov](http://fda.gov), [ClinicalTrials.gov](http://clinicaltrials.gov), abstracts from individual congress proceedings, the [Cochrane.org](http://cochrane.org) library, and the EMBASE database between January 1, 1990 and June 30, 2019. The search terms used were "pancreatic cancer", "gemcitabine", "FOLFOX", 5-fluorouracil", "oxaliplatin", and "leucovorin".

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Trials meeting the following criteria were included in the meta-analysis: 1) patients with locally advanced and metastatic disease, 2) patients who received prior gemcitabine-containing treatment, 3) second-line treatment regimens included 5-FU and oxaliplatin, and 4) reported data included median OS, severe (Grades 3--4) treatment-related adverse events (TRAEs), based on the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 \[[@CR25]\]. Trials meeting the following criteria were excluded from the meta-analysis: 1) patients who received prior treatment with 5-FU and oxaliplatin for locally advanced or metastatic pancreatic cancer, 2) patients who received an oral fluoropyrimidine, or irinotecan, capecitabine, or cisplatin as second-line treatment, and 3) patient PS was not reported.

Data collection and analysis {#Sec5}
----------------------------

Two reviewers independently evaluated the literature identified from the database searches. For studies reported in different publications, the most recent study was retained, and the other version was excluded. The information extracted from each study included author names, publication year, number of patients, number of survival events, median OS, and severe adverse events. Any discrepancies in study eligibility or data extraction were reconciled. Studies were excluded if the full text of the publication was not available or if PS or median OS data were not reported.

Statistical analyses {#Sec6}
--------------------

The primary endpoint and secondary endpoints were median OS and severe TRAEs for patients who received FOLFOX or 5-FU/oxaliplatin--based therapy following prior gemcitabine--based regimens for metastatic pancreatic cancer. Adjusted PS was included in the meta-analysis model as follows. To standardize the trial-level PS, Karnofsky grade was converted to ECOG Grade according to Oken et al. \[[@CR26]\], and the overall study-weighted PS was calculated based on the weighted average. For example, ECOG 0--1 was converted to numerical value 1, and ECOG 2, 3, and 4 were converted to numerical values 2, 3, and 4, respectively. For a study with *w*~1~% of the patients had ECOG 0--1 and *w*~2~% with ECOG 2. The weighted trial performance was calculated as: 1× *w*~1~% + 2× *w*~2~%. A Bayesian fixed-effect meta-analysis was performed for the median OS with weighted trial PS as a predictor. A noninformative prior was used to establish the relationship between log transformation of median OS and PS. The noninformative prior was assumed for the related parameters. The posterior median of OS and 95% posterior interval (PI) were summarized for patients with ECOG PS ≤1. For safety, Grade 3/4 clinically relevant toxicities that were reported in ≥10% of patients in any trial were pooled together to evaluate the toxicity of the treatment regimen. To be conservative, trials that did not report a specific adverse event were removed from the group of evaluable patients. All analyses were performed in R 3.5.0.

Results {#Sec7}
=======

Study selection {#Sec8}
---------------

The CONSORT flow chart that illustrates study identification and selection for the meta-analysis is shown in Fig. [1](#Fig1){ref-type="fig"}. Of 282 studies identified in the database searches, 11 were chosen for meta-analysis \[[@CR14]--[@CR16], [@CR24], [@CR27]--[@CR33]\], and 242 studies were excluded. In total, 454 patients with pancreatic cancer were included in this meta-analysis. The 11 selected studies evaluated 5-FU and oxaliplatin-based regimens, including OFF, FOLFOX, and modified FOLFOX (mFOLFOX6, mFOLFOX4) (Table [1](#Tab1){ref-type="table"}). Fig. 1CONSORT diagramTable 1Summary of 5-FU and oxaliplatin-based therapy as second-line therapyTreatmentAuthor/year*N*Weighted PSOriginal PSPrior surgery (%)DeathsMedian OS (m)ORR (%)OFFPelzer 2009 \[[@CR28]\]371.5KS: Median: 70, range: \[60, 90\]43335.16OFFPelzer 2011 \[[@CR27]\]231.3KS: Median: 80, range: \[70, 100\]NR184.80OFFOettle 2014 \[[@CR14]\]761.2KS: (90--100) (53.9%), 70--80 (46.1%)45735.9175-FU/OXA-basedTsavaris 2005 \[[@CR29]\]301.7KS: (80--100) (33.4%), 70--50 (66.7%)NR205.723FOLFOXGebbia 2007 \[[@CR30]\]421.4ECOG: 1 (62%), 2 (38%)9386.714FOLFOXYoo 2009 \[[@CR31]\]301.0ECOG: 0--1 (97%)32253.87FOLFOXZaanan 2014 \[[@CR24]\]121.0ECOG: 0--1 (100%)0105.90FOLFOXZaanan 2014 \[[@CR24]\]122.5ECOG: 2--3 (100%)0122.60FOLFOXGill 2016 \[[@CR16]\]541.1ECOG: 0--1 (89%), 2 (11%)NR476.113FOLFOXBerk 2012 \[[@CR32]\]461.2ECOG: 0--1 (78%), 2 (22%)NR33.66.217OFFEl-Hadaad 2013 \[[@CR33]\]301.2ECOG: 0--1 (83.4%), 2 (16%)NR295.17FOLFOXChung 2017 \[[@CR15]\]621.0ECOG: 0--1 (100%)NR536.711Abbreviations: *5-FU* 5-fluorouracil, *ECOG* Eastern Cooperative Oncology Group, *FOLFOX* leucovorin/5-fluorouracil/oxaliplatin, *m* months, *KS* Karnofsky status, *NR* not reported, *OFF* oxaliplatin/5-fluorouracil/leucovorin, *ORR* overall response rate, *OS* overall survival, *OXA* oxaliplatin, *PS* performance score

Patient population {#Sec9}
------------------

In the 454 evaluable patients, the reported PS ranged from Karnofsky performance index scores of 60--100 and ECOG PS scale scores of 0--3 (Table [1](#Tab1){ref-type="table"}). Of 11 studies, five reported the surgical histories of the patient sample. Rates of prior surgery were 8% \[[@CR34]\], 9% \[[@CR30]\], 32% \[[@CR31]\], 43% \[[@CR28]\], and 45% \[[@CR14]\]. The median OS ranged from 2.6 months to 6.7 months, and the overall response rate ranged from 0 to 23% (Table [1](#Tab1){ref-type="table"}).

Overall survival {#Sec10}
----------------

Baseline weighted PS scores predicted OS in 10 of the 11 studies (Fig. [2](#Fig2){ref-type="fig"}). Results from one study were identified as an outlier, with a median OS of approximately 4 months in patients with a baseline weighted PS score of 1.0 \[[@CR31]\]. Likely the variability was because of a long period of time between the conclusion of gemcitabine-based therapy to FOLFOX treatment (median 15 weeks, range 7.0--32.6 weeks). To maintain integrity of the analysis, the outlier was not removed from the model. Based on the Bayesian meta-analysis with the adjustment of baseline PS, for 5-FU and oxaliplatin-based therapy (Fig. [3](#Fig3){ref-type="fig"}), the median OS was 6.2 months (95% PI 5.4--7.1). For the analysis of FOLFOX therapy (Fig. [4](#Fig4){ref-type="fig"}), the median OS was 6.3 months (95% PI 5.4--7.4). Fig. 2Association between median overall survival (OS) and patient performance statusFig. 3Overall survival (OS) meta-analysis of 5-fluorouracil (5-FU) and oxaliplatin (OXA)-based therapyFig. 4Overall survival (OS) meta-analysis of FOLFOX

Safety of FOLFOX {#Sec11}
----------------

The clinically relevant Grade 3--4 TRAEs for the selected studies were pooled, and the results are summarized in Table [2](#Tab2){ref-type="table"}. The most commonly reported Grade 3--4 TRAEs associated with FOLFOX therapy were neutropenia (21.5%) and fatigue (11.7%). Other Grade 3--4 TRAEs occurring in \> 10% in any trial were neurotoxicity (5.3%), thrombocytopenia (4.9%), anemia (4.5%), diarrhea (4.2%), and vomiting (4.1%). Table 2Summary of safety for 5-FU and oxaliplatin-based therapyTreatmentAuthor/year*N*Grade 3--4 clinically relevant toxicities \> 10% in any trialDiarrheaNeutropeniaAnemiaNeurotoxicityFatigue^a^VomitingThrombocytopeniaOFFPelzer 2009 \[[@CR28]\]378.1NRNR10.8NR13.50OFFPelzer 2011 \[[@CR27]\]238.7NRNRNRNRNRNROFFOettle 2014 \[[@CR14]\]761.3NR3.9NRNR1.31.35-FU/OXA-basedTsavaris 2005 \[[@CR29]\]3014.2NR3.24.2003.2FOLFOXGebbia 2007 \[[@CR30]\]42NR171412NRNR7FOLFOXYoo 2009 \[[@CR31]\]300203014103FOLFOXZaanan 2014 \[[@CR24]\]2707.47.47.414.8011.1FOLFOXGill 2016 \[[@CR16]\]49232.724.114.24.18.2FOLFOXBerk 2012 \[[@CR32]\]462220NRNR27OFFEl-Hadaad 2013 \[[@CR33]\]303.323.26.66.6NR3.36.6FOLFOXChung 2017 \[[@CR15]\]626.5NR3.2012.94.8NREvaluable patients for each AE, *n*410224392307198387367Weighted average (%)4.221.54.55.311.74.14.9Abbreviations: *5-FU* 5-fluorouracil, *AE* adverse event, *FOLFOX* leucovorin/5-fluorouracil/oxaliplatin, *N* patients in each study, *n* evaluable patients for each AE, *NR* not reported, *OFF* oxaliplatin/5-fluorouracil/leucovorin, *OXA* oxaliplatin^a^Fatigue includes reported terms of fatigue and asthenia

Discussion {#Sec12}
==========

The prognosis of pancreatic cancer remains dismal, and the primary first-line treatments for patients with metastatic disease are gemcitabine-based combinations and FOLFIRINOX. For patients previously treated with gemcitabine, second-line 5-FU--based therapy including FOLFIRI, FOLFOX, and OFF have been recommended \[[@CR6]\]. In randomized trials, oxaliplatin--based regimens in the second-line setting, such as CONKO-003 and PANCREOX, have had conflicting efficacy results \[[@CR35]\]. In the CONKO-003 trial, the OFF regimen was superior to FF (leucovorin and 5-FU) with a median OS of 5.9 vs. 3.3 months, respectively \[[@CR14]\]. On the other hand, the PANCREOX study compared a different oxaliplatin, 5-FU, and leucovorin-containing regimen (mFOLFOX6) with 5-FU/LV, with a median OS of 6.1 vs. 9.9 months, respectively \[[@CR16]\]. While mFOLFOX6 produced results consistent with prior studies of oxaliplatin and 5-FU combinations, the 5-FU/LV control arm demonstrated surprisingly prolonged survival. One factor that may have contributed to these findings was an imbalance in several baseline characteristics. For example, the median time from diagnosis of advanced disease to treatment was longer in the mFOLFOX6 arm compared with the 5-FU/LV arm (7.9 vs. 5.7 months, respectively), and a higher proportion of patients in the mFOLFOX6 arm than in the 5-FU/LV arm had baseline ECOG PS scores of 2 (11.1% vs. 5.7%). Additionally, fewer patients in the mFOLFOX6 arm than the 5-FU/LV arm received post-discontinuation therapy (7% vs. 23%, respectively). It is important to remember that these are relatively small studies of fewer than 200 patients each, and comparisons are fraught because of inherent methodologic differences.

The systematic literature review and meta-analysis reported here was conducted in an attempt to overcome the variability induced by small sample sizes. In addition, after adjusting for PS, the meta-analysis of 5-FU and oxaliplatin-based therapy (e.g., FOLFOX) demonstrated a numerically similar treatment effect (median OS range 2.6--6.7 months; Table [1](#Tab1){ref-type="table"}) compared with 5-FU/LV plus nanoliposomal irinotecan combination therapy in the NAPOLI-1 trial (median OS 6.1 months; 95% CI 4.8--8.9) (Table [3](#Tab3){ref-type="table"}) \[[@CR12]\]. For patients with ECOG PS of 0 or 1, the median OS was 6.2 months (95% PI 5.4--7.1) for patients who received the oxaliplatin, 5-FU, and LV regimen. In addition, for the subset meta-analysis of FOLFOX therapy (Fig. [4](#Fig4){ref-type="fig"}), the median OS demonstrated consistent results with median OS of 6.3 months (95% PI 5.4--7.4). The most commonly reported Grade 3--4 TRAEs associated with FOLFOX therapy were neutropenia (21.5%) and fatigue (11.7%). Other Grade 3--4 TRAEs occurring in \> 10% in any trial were neurotoxicity (5.3%), thrombocytopenia (4.9%), anemia (4.5%), diarrhea (4.2%), and vomiting (4.1%) (Table [2](#Tab2){ref-type="table"}). Based on an indirect comparison, this adverse event profile was similar to the findings of the NAPOLI-1 trial (Table [4](#Tab4){ref-type="table"}). Table 3Baseline and efficacy profile for nanoliposomal irinotecan-based therapy from NAPOLI-1 \[[@CR12]\]Characteristics^a^Results*N*117Karnofsky performance 100--8091%Lines of prior therapy: 0/1/2+ (%)13/53/34Prior therapy:Gemcitabine mono/combination/5-FU-based (%)45/55/43Median OS (95% CI)6.1 months (4.8--8.9)Abbreviations: *5-FU* 5-fluorouracil, *CI* confidence interval, *ECOG* Eastern Cooperative Oncology Group, *N* patients in study, *OS* overall survival^a^For patients with ECOG 0--1, the poster median of the median OS for 5-FU and oxaliplatin-based therapy and FOLFOX in second-line are 6.2 months and 6.3 months, respectivelyTable 4Safety profile for nanoliposomal irinotecan-based therapy \[[@CR12]\]Grade 3--4 AEsNanoliposomal irinotecan-based therapy (%)5-FU and OXA-based therapy weighted average (%) \[range\]Diarrhea134.2 \[0, 14.2\]Vomiting114.1 \[0, 13.5\]Fatigue1411.7 \[0, 14.8\]Neutropenia2721.5 \[7.4, 32.7\]Anemia94.5 \[0, 14\]Hypokalemia3NRNeurotoxicityNR5.3 \[0, 12\]ThrombocytopeniaNR4.9 \[0, 11.1\]Abbreviations: *5-FU* 5-fluorouracil, *AE* adverse event, *NR* not recorded, *OXA* oxaliplatin

These analyses are not without limitations. Our ability to adjust survival outcomes for other potential prognostic factors was hindered because we did not have access to the full study datasets. For example, prior surgery, levels of the CA-19-9 antigen, baseline hemoglobin levels, *BRCA1* or *BRCA2* mutation status, or the time from diagnosis to the initiation of treatment were not always reported. In addition, the cross-trial comparison between the meta-analysis of the FOLFOX treatment regimen and the results from NAPOLI-1 are indirect and must be interpreted with caution.

Conclusions {#Sec13}
===========

In this meta-analysis, we confirmed that baseline PS is a strong prognostic factor when interpreting the efficacy of 5-FU and oxaliplatin-based therapy after progression of pancreatic cancer with first-line gemcitabine-containing therapies. After adjusting for patient PS, the meta-analysis of 5-FU and oxaliplatin-based therapy (e.g., FOLFOX) shows a numerically similar treatment effect as 5-FU and nanoliposomal irinotecan therapy in the NAPOLI-1 trial. In addition, the adverse event profile is also comparable between the two treatment regimens. The findings from our analyses suggest that the combination of 5-FU and oxaliplatin-based therapies remains an acceptable and alternative second-line treatment option for patients with pancreatic cancer and adequate PS (e.g., ECOG 0/1) who have received gemcitabine-based therapies.
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